

AMENDMENTS TO THE CLAIMS:

The present listing of the claims will replace all previous claim listings as follows:

1-7. (Cancelled).

8. (Currently amended) ~~The device according to claim 1A~~ device for urinary catheterization comprising a catheter element adapted to be inserted in the urethra of a human, wherein at least a part of said catheter element on the outer surface, before insertion of the catheter element, has a hydrophilic polymer coating, and at least a portion of said polymer coating is impregnated with a pharmaceutically active composition, said pharmaceutically active composition having at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, and said pharmaceutically active composition being coated with a water soluble coating such that the pharmaceutically active composition is delivered to the lower urinary tract system during catheterization.

9. (Cancelled).

10. (Previously presented) The device according to claim 9, wherein said hydrophilic polymer coating is impregnated with at least a portion of said pharmaceutically active composition.

11. (Currently amended) The device according to claim ~~1~~ 8, wherein said catheter element further comprises at least one or more depressions on the outer surface, wherein said depressions are capable of containing at least a portion of said pharmaceutically active composition.

12. (Currently amended) The device according to claim ~~1~~ 8, wherein at least a portion of said pharmaceutically active composition is provided in a gel or cream formulation.

13. (Currently amended) The device according to claim ~~1~~ 8, wherein said device further comprises a lubricating gel adapted to reduce friction between the catheter element and urethra, and said gel contains at least a portion of said pharmaceutically active composition.

14. (Currently amended) The device according to claim ~~1~~ 8, wherein

said device comprises a discrete unit dose containing said pharmaceutically active composition, and said device is adapted to deliver said discrete unit dose in the lower urinary tract.

15. (Currently amended) The device according to claim ~~1~~ 8, wherein said hormone is a female sex hormone or a derivative thereof.

16. (Previously presented) The device according to claim 15, wherein said hormone is selected from estrogen or an estrogen derivative.

17. (Previously presented) The device according to claim 15, wherein said hormone is estriol or estradiol.

18. (Currently amended) The device according to claim ~~1~~ 8, wherein said pharmaceutically active composition comprises an efferent blocking agent selected from the group consisting of anti-cholinergical agents, sympathomimetics agents, alfa-adrenergic agonists and nicotinic cholinergic agonists.

19. (Previously presented) The device according to claim 18, wherein said efferent agent is oxybutynin or trospiumchlorid.

20. (Currently amended) The device according to claim ~~1~~ 8, wherein said pharmaceutically active composition comprises an afferent blocking agent.

21. (Currently amended) The use of a pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, for the manufacture of a device for the treatment, alleviation or prophylaxis of incontinence in a human, said device comprising a catheter element adapted for intermittent catheterization of the urethra of a human, wherein at least a part of said catheter element on the outer surface, before insertion of the catheter element, has a hydrophilic polymer coating, and at least a portion of said polymer coating is impregnated with a pharmaceutically active composition, said pharmaceutically active composition having at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, and said pharmaceutically active composition being coated with a water soluble coating such that the pharmaceutically active composition is delivered to the lower urinary tract system during

~~catheterization said catheter element having the pharmaceutically active composition, and said catheter element being adapted to deliver said agent in the lower urinary tract during catheterization.~~

22. (Original) The use according to claim 21, wherein the human is a female.

23. (Cancelled).

24. (Currently amended) A method of treating a human suffering from or being susceptible to incontinence, the method comprising the steps of catheterization of said human by arranging a proximal end of a catheter element of a device adapted for intermittent urinary catheterization in the urethra of said human, wherein at least a part of said catheter element on the outer surface, before insertion of the catheter element, has a hydrophilic polymer coating, and at least a portion of said polymer coating is impregnated with a pharmaceutically active composition, said pharmaceutically active composition having at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, and

said pharmaceutically active composition being coated with a water soluble coating such that the pharmaceutically active composition is delivered to the lower urinary tract system during catheterizationsaid catheter element comprising a pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, and said catheter element being adapted to deliver said composition into the lower urinary tract of said human during catheterization.

25. (Original) The method according to claim 24, wherein the human is a female.

26. (Cancelled).

27. (Currently amended) A kit comprising a device for urinary catheterization and a pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, said device comprising a catheter element adapted for intermittent catheterization of the urethra of a human, wherein at least a part of said catheter element on the outer

surface, before insertion of the catheter element, has a hydrophilic polymer coating, and at least a portion of said polymer coating is impregnated with a pharmaceutically active composition, said pharmaceutically active composition having at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, and said pharmaceutically active composition being coated with a water soluble coating such that the pharmaceutically active composition is delivered to the lower urinary tract system during catheterization.

28. (Currently amended) A The device for urinary catheterization of claim 8, ~~said device comprising a catheter element adapted for intermittent catheterization with a proximal end adapted to be inserted into a urinary canal of a human, wherein said device comprises a discrete unit dose, said discrete unit dose contains of a said pharmaceutically active composition comprising at least one agent selected from the group consisting of hormones, efferent blocking agents, afferent blocking agents and sympathomimetic agents, and said catheter element being adapted to deliver said pharmaceutically active composition in the lower urinary tract during catheterization.~~

USSN 10/538,832
Atty Dkt No. P68468US1

29. (Currently amended) The device according to claim 28, wherein said discrete unit dose is placed at the ~~distal~~ proximal end of the catheter.